The DOI matches its Crossref record; 98 of the 99 references it cites were found in a registry or an index.
Glucagon-like Peptide–1 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents
Abstract
Novel therapeutic options for type 2 diabetes mellitus based on the action of the incretin hormone glucagon-like peptide (GLP)-1 were introduced in 2005. As injectable GLP-1 receptor agonists acting on the GLP-1 receptor, exenatide and liraglutide are available in many countries. In type 2 diabetes treatment, incretin-based therapies are attractive and more commonly used because of their mechanism of action and safety profile. Stimulation of insulin secretion and inhibition of glucagon secretion by these agents occur in a glucose-dependent manner. Therefore, incretin-based therapies have no intrinsic risk for hypoglycaemia. Furthermore, GLP-1 receptor agonists allow weight loss and lower systolic blood pressure. This review gives a brief overview of the mechanism of action and summarizes the clinical data available on exenatide and liraglutide as established substances. It further highlights the clinical study data of exenatide once weekly as the first long-acting GLP-1 receptor agonist and covers other new long acting GLP-1 receptor agonists currently in clinical development. The placement of GLP-1 receptor agonists in the treatment algorithm of type 2 diabetes is discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In 2005, a new treatment of T2DM based on the action of GLP-1 was introduced (137).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [137]
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 2×
“On the other hand, the 10-year follow-up data of the UKPDS (United Kingdom Prospective Diabetes Study) show that an early and effective diabetes treatment not only lowers microvascular complications, but also macrovascular endpoints significantly.([5]) In view of these findings, patients with newly diagnosed type 2 di…”
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 8×
“of isolated human islets in cell culture([14,24,96]) gives rise to the hypothesis that incretin-based therapies might also prove advantageous in type 1 diabetes alone or in combination with immune therapy.”
InfluentialNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 3×
“of isolated human islets in cell culture([14,24,96]) gives rise to the hypothesis that incretin-based therapies might also prove advantageous in type 1 diabetes alone or in combination with immune therapy.”
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465 · cited 1×
“The microvascular and macrovascular complication risk can be lowered by improved metabolic control.([3-5]) However, further important treatment goals such as body weight reduction or the prevention of hypoglycaemia are seldom accomplished.”
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 1×
“GLP-1 additionally binds to its receptor on hypothalamic neurons and stimulates satiety by direct action; GLP-1 is present in hypothalamic neurons,([16]) but exogenously administered GLP-1 or GLP-1 receptor agonists are able to cross the blood-brain barrier.”
Islet cell failure in type 2 diabetes
Prentki, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29103 · Cited by 1,690 · cited 1×
“This functional loss is characterized by an increasing defect in the insulin response to glucose as well as a loss of b-cell mass over time.([7,8])”
Research works printed but not linked: 3
- Klonoff, 2008, Curr Med Res Opin, 24, 275, 10.1185/030079907X253870 · doi:10.1185/030079907x253870 · Paper page
- Ahmad, 2008, N Engl J Med, 358, 1970
- Garber, 2008, J Fam Pract, 57, S10
Cited by
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248
Bharucha, A. E., Kudva, Y. C., & Prichard, D. O. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00161 · Cited by 252
Wang, B., Zhong, J., Lin, H., Zhao, Z., Yan, Z., He, H., Ni, Y., Liu, D., & Zhu, Z. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12085 · Cited by 225
van Baar, M. J. B., van Ruiten, C. C., Muskiet, M. H. A., van Bloemendaal, L., IJzerman, R. G., & van Raalte, D. H. (2018) · Diabetes Care · doi:10.2337/dc18-0588 · Cited by 199
Conlon, J. M., Mechkarska, M., Lukic, M. L., & Flatt, P. R. (2014) · Peptides · doi:10.1016/j.peptides.2014.04.019 · Cited by 185
Metadata
- Authors
- Gallwitz, B.
- Affiliations
- University of Tübingen (DE)
- Corresponding author
- Gallwitz, Baptist
- ORCID
- Gallwitz, Baptist
- Venue
- Drugs
- Published
- 2011-09
- Volume
- 71
- Issue
- 13
- Pages
- 1675-1688
- ISSN
- 0012-6667 (ISSN-L)
- OpenAlex
- W188703145
- Cited by
- 142
- References
- 99
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 11 · 2023: 9 · 2022: 2 · 2021: 7 · 2020: 8 · 2019: 6 · 2018: 5 · 2017: 11 · 2016: 9 · 2015: 11 · 2014: 12 · 2013: 20 · 2012: 22
- FWCI
- 2.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, exenatide, liraglutide, exenatide once weekly, long-acting GLP-1 receptor agonists, incretin-based therapy, insulin secretion, glucagon secretion, weight loss, blood pressure reduction, treatment algorithm
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Peptides, Venoms, Receptors, Glucagon, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucagon-like Peptide–1 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents. https://app.cochat.ai/papers/10.2165/11592810-000000000-00000
- The paper
- Gallwitz, B. (2011). Glucagon-like Peptide–1 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents. Drugs. https://doi.org/10.2165/11592810-000000000-00000
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.